Preventing contrast-induced nephropathy in patients with baseline renal dysfunction undergoing coronary angiography

Current Treatment Options in Cardiovascular Medicine

Volumn 11, Issue 1, 2009, Pages 71-78

  Lee, Po Tsang ^a   Chou, Kang Ju ^a   Fang, Hua Chang ^a  

^a KAOHSIUNG VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; AMINOGLYCOSIDE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BICARBONATE; CONTRAST MEDIUM; DIATRIZOATE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IODIXANOL; IOHEXOL; IOPAMIDOL; IOVERSOL; IOXAGLIC ACID; LOOP DIURETIC AGENT; METFORMIN; NONSTEROID ANTIINFLAMMATORY AGENT;

ANGIOCARDIOGRAPHY; CLINICAL TRIAL; DEHYDRATION; DISEASE SEVERITY; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; FIRST PASS EFFECT; HEART MUSCLE ISCHEMIA; HEMODIALYSIS; HUMAN; KIDNEY DISEASE; KIDNEY DYSFUNCTION; KIDNEY INJURY; OSMOLALITY; PERCUTANEOUS CORONARY INTERVENTION; REHYDRATION; RENAL REPLACEMENT THERAPY; REVIEW; RISK ASSESSMENT; SURVIVAL; VISCOSITY;

EID: 58449084681     PISSN: 10928464     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11936-009-0008-6     Document Type: Review

References (51)

1. Nash K, Hafeez A, Hou S: Hospital-acquired renal insufficiency. Am J Kidney Dis 2002, 39: 930-936.
2. Manske CL, Sprafka JM, Strony JT, Wang Y: Contrast nephropathy in azotemic diabetic patients undergoing coronary angiography. Am J Med 1990, 89: 615-620.
3. McCullough PA, Adam A, Becker CR, et al.: Risk prediction of contrast-induced nephropathy. Am J Cardiol 2006, 98: 27K-36K.
4. Madyoon H, Croushore L, Weaver D, Mathur V: Use of fenoldopam to prevent radiocontrast nephropathy in high-risk patients. Catheter Cardiovasc Interv 2001, 53: 341-345.
5. McCullough PA, Wolyn R, Rocher LL, et al.: Acute renal failure after coronary intervention: Incidence, risk factors, and relationship to mortality. Am J Med 1997, 103: 368-375.
6. Dangas G, Iakovou I, Nikolsky E, et al.: Contrast-induced nephropathy after percutaneous coronary interventions in relation to chronic kidney disease and hemodynamic variables. Am J Cardiol 2005, 95: 13-19.
7. Rihal CS, Textor SC, Grill DE, et al.: Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 2002, 105: 2259-2264.
8. Gruberg L, Mintz GS, Mehran R, et al.: The prognostic implications of further renal function deterioration within 48 h of interventional coronary procedures in patients with pre-existent chronic renal insufficiency. J Am Coll Cardiol 2000, 36: 1542-1548.
9. Lindsay J, Apple S, Pinnow EE, et al.: Percutaneous coronary intervention associated nephropathy foreshadows increased risk of late adverse events in patients with normal baseline serum creatinine. Catheter Cardiovasc Interv 2003, 59: 338-343.
10. Subramanian S, Tumlin J, Bapat B, et al.: Economic burden of contrast-induced nephropathy: Implications for prevention strategies. J Med Econ 2007, 10: 119-134.
11. Solomon R, Werner C, Mann D, et al.: Effects of saline, mannitol, and furosemide to prevent acute decreases in renal function induced by radiocontrast agents. N Engl J Med 1994, 331: 1416-1420.
12. Mueller C, Buerkle G, Buettner HJ, et al.: Prevention of contrast media-associated nephropathy: Randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty. Arch Intern Med 2002, 162: 329-336.
13. Merten GJ, Burgess WP, Gray LV, et al.: Prevention of contrast-induced nephropathy with sodium bicarbonate: A randomized controlled trial. JAMA 2004, 291: 2328-2334.
14. Masuda M, Yamada T, Mine T, et al.: Comparison of usefulness of sodium bicarbonate versus sodium chloride to prevent contrast-induced nephropathy in patients undergoing an emergent coronary procedure. Am J Cardiol 2007, 100: 781-786.
15. Krasuski RA, Beard BM, Geoghagan JD, et al.: Optimal timing of hydration to erase contrast-associated nephropathy: The OTHER CAN study. J Invasive Cardiol 2003, 15: 699-702.
16. Bader BD, Berger ED, Heede MB, et al.: What is the best hydration regimen to prevent contrast media-induced nephrotoxicity? Clin Nephrol 2004, 62: 1-7.
17. Dussol B, Morange S, Loundoun A, et al.: A randomized trial of saline hydration to prevent contrast nephropathy in chronic renal failure patients. Nephrol Dial Transplant 2006, 21: 2120-2126.
18. Davidson C, Stacul F, McCullough PA, et al.: Contrast medium use. Am J Cardiol 2006, 98: 42K-58K.
19. Barrett BJ, Carlisle EJ: Metaanalysis of the relative nephrotoxicity of high- and low-osmolality iodinated contrast media. Radiology 1993, 188: 171-178.
20. Sharma SK, Kini A: Effect of nonionic radiocontrast agents on the occurrence of contrast-induced nephropathy in patients with mild-moderate chronic renal insufficiency: Pooled analysis of the randomized trials. Catheter Cardiovasc Interv 2005, 65: 386-393.
21. Solomon R: The role of osmolality in the incidence of contrast-induced nephropathy: A systematic review of angiographic contrast media in high risk patients. Kidney Int 2005, 68: 2256-2263.
22. Solomon R, Dumouchel W: CoFtrast media and nephropathy: findings from systematic analysis and Food and Drug Administration reports of adverse effects. Invest Radiol 2006, 41: 651-660.
23. Solomon RJ, Natarajan MK, Doucet S, et al.: Cardiac Angiography in Renally Impaired Patients (CARE) study: A randomized double-blind trial of contrast-induced nephropathy in patients with chronic kidney disease. Circulation 2007, 115: 3189-3196.
24. Kuhn MJ, ChenAN, Sahani DV, et al.: The PREDICT study: a randomized double-blind comparison of contrast-induced nephropathy after low- or isoosmolar contrast agent exposure. AJR Am J Roentgenol 2008, 191: 151-157.
25. McCullough PA, Adam A, Becker CR, et al.: Risk prediction of contrast-induced nephropathy. Am J Cardiol 2006, 98: 27K-36K.
26. Freeman RV, O'Donnell M, Share D, et al.: Nephropathy requiring dialysis after percutaneous coronary intervention and the critical role of an adjusted contrast dose. Am J Cardiol 2002, 90: 1068-1073.
27. Mehran R, Aymong ED, Nikolsky E, et al.: A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: Development and initial validation. J Am Coll Cardiol 2004, 44: 1393-1399.
28. Cigarroa RG, Lange RA, Williams RH, Hillis LD: Dosing of contrast material to prevent contrast nephropathy in patients with renal disease. Am J Med 1989, 86: 649-652.
29. Freeman R: Nephropathy requiring dialysis after percutaneous coronary intervention and the critical role of an adjusted contrast dose. Am J Cardiol 2002, 90: 1068-1073.
30. Laskey WK, Jenkins C, Selzer F, et al.: Volume-to-creatinine clearance ratio: A pharmacokinetically based risk factor for prediction of early creatinine increase after percutaneous coronary intervention. J Am Coll Cardiol 2007, 50: 584-590.
31. Borgstrom L, Kagedal B, Paulsen O: Pharmacokinetics of N-acetylcysteine in man. Eur J Clin Pharmacol 1986, 31: 217-222.
32. Bonanomi L, Gazzaniga A: Toxicological, pharmacokinetic and metabolic studies on acetylcysteine. Eur J Respir Dis 1980, 61: 45-51.
33. Sjodin K, Nilsson E, Hallberg A, Tunek A: Metabolism of N-acetyl-l-cysteine. Biochem Pharm 1989, 38: 3981-3985.
34. Tepel M, van der Giet M, Schwarzfeld C, et al.: Prevention of radiographic contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med 2000, 343: 180-184.
35. Birck R, Krzossok S, Markowetz F, et al.: Acetylcysteine for prevention of contrast nephropathy: Meta-analysis. Lancet 2003, 362: 598-603.
36. Pannu N, Manns B, Lee H, Tonelli M: Systematic review of the impact of N-acetylcysteine on contrast nephropathy. Kidney Int 2004, 65: 1366-1374.
37. Kshirsagar AV, Poole C, Mottl A, et al.: N-acetylcysteine for the prevention of radiocontrast induced nephropathy: A meta-analysis of prospective controlled trials. J Am Soc Nephrol 2004, 15: 761-769.
38. Duong MH, MacKenzie TA, Malenka DJ: N-acetylcysteine prophylaxis significantly reduces the risk of radiocontrast-induced nephropathy: comprehensive meta-analysis. Catheter Cardiovasc Interv 2005, 64: 471-479.
39. Zagler A, Azadpour M, Mercado C, Hennekens CH: N-acetylcysteine and contrast-induced nephropathy: A meta-analysis of 13 randomized trials. Am Heart J 2006, 151: 140-145.
40. Hoffmann U, Fischereder M, Kruger B, et al.: The value of N-acetylcysteine in the prevention of radiocontrast agent-induced nephropathy seems questionable. J Am Soc Nephrol 2004, 15: 407-410.
41. Haase M, Haase-Fielitz A, Ratnaike S, et al.: N-acetylcysteine does not artificially lower plasma creatinine concentration. Nephrol Dial Transplant 2008, 23: 1581-1587.
42. Recio-Mayoral A, Chaparro M, Prado B, et al.: The renoprotective effect of hydration with sodium bicarbonate plus N-acetylcysteine in patients undergoing emergency percutaneous coronary intervention: The RENO Study. J Am Coll Cardiol 2007, 49: 1283-1288.
43. Briguori C, Airoldi F, D'Andrea D, et al.: Renal Insufficiency Following Contrast Media Administration Trial (REMEDIAL): A randomized comparison of 3 preventive strategies. Circulation 2007, 115: 1211-1217.
44. Lorusso V, Taroni P, Alvino S, Spinazzi A: Pharmacokinetics and safety of iomeprol in healthy volunteers and in patients with renal impairment or end stage renal disease requiring haemodialysis. Invest Radiol 2001, 36: 309-316.
45. Waaler A, Svaland M, Fauchald P, et al.: Elimination of iohexol, a low osmolar nonionic contrast medium, by hemodialysis in patients with chronic renal failure. Nephron 1990, 56: 81-85.
46. Ueda J, Furukawa T, Takahashi S, et al.: Elimination of ioversol by hemodialysis. Acta Radiol 1996, 37: 826-829.
47. Matzkies FK, Reinecke H, Tombach B, et al.: Influence of dialysis procedure, membrane surface and membrane material on iopromide elimination in patients with reduced kidney function. Am J Nephrol 2000, 20: 300-304.
48. Cruz DN, Perazella MA, Bellomo R, et al.: Extracorporeal blood purification therapies for prevention of radiocontrast-induced nephropathy: A systematic review. Am J Kidney Dis 2006, 48: 361-371.
49. Lee PT, Chou KJ, Liu CP, et al.: Renal protection for coronary angiography in advanced renal failure patients by prophylactic hemodialysis. A randomized controlled trial. J Am Coll Cardiol 2007, 50: 1015-1020.
50. Marenzi G, Marana I, Lauri G, et al.: The prevention of radiocontrast agent-induced nephropathy by hemofiltration. N Engl J Med 2003, 349: 1333-1340.
51. Marenzi G, Lauri G, Campodonico J, et al.: Comparison of two hemofiltration protocols for prevention of contrast-induced nephropathy in high-risk patients. Am J Med 2006, 119: 155-162.